Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00253474
Other study ID # 050232
Secondary ID 05-C-0232NCI-P66
Status Completed
Phase Phase 1
First received November 11, 2005
Last updated March 28, 2012
Start date September 2005
Est. completion date January 2011

Study information

Verified date March 2012
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon alfa-2b in treating young patients with plexiform neurofibroma.


Description:

OBJECTIVES:

Primary

- Determine the maximum tolerated dose of PEG-interferon alfa-2b in patients with unresectable plexiform neurofibroma. (Dose escalation portion of study closed to accrual as of 2/2005.)

- Determine the toxicity profile of this drug in these patients.

Secondary

- Obtain, preliminary, information about the efficacy of this drug in these patients.

- Evaluate the growth rate of plexiform neurofibroma using volumetric MRI analysis in patients treated with this drug.

- Evaluate the impact of this drug, in terms of "worst symptom" score, in these patients.

OUTLINE: This is a dose-escalation, multicenter study. (Dose-escalation portion of the study closed to accrual as of 2/2005.)

Patients receive PEG-interferon alfa-2b subcutaneously once weekly for 2 years in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of PEG-interferon alfa-2b until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 1 of 6 patients experience dose-limiting toxicity. A total of 12 patients receive treatment at the MTD.

After completion of study treatment, patients are followed every 6 months.

PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.


Other known NCT identifiers
  • NCT00156754

Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date January 2011
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 1 Year to 21 Years
Eligibility DISEASE CHARACTERISTICS:

- Diagnosis of plexiform neurofibroma which is progressive, symptomatic, or life threatening and for which there is no other standard medical management or surgical option

- Histologic confirmation of tumor is not required in the presence of consistent clinical and radiographic findings provided the following are true:

- No clinical observation or scan suggestive of malignant transformation

- Meets = 1 of the following diagnostic criteria for neurofibroma type 1 (NF1):

- Six or more cafe-au-lait spots (> 0.5 cm in prepubertal patients or > 1.5 cm in post pubertal patients)

- Freckling in axilla or groin

- Optic glioma

- Two or more Lisch nodules

- A distinctive bony lesion (e.g., dysplasia of the sphenoid bone, dysplasia, or thinning of long bone cortex)

- A first degree relative with NF1

- No history of malignant peripheral nerve sheath tumor

- No active visual pathway glioma

- No active brain tumor or brain metastases

PATIENT CHARACTERISTICS:

Performance status

- ECOG 0-2

Life expectancy

- At least 12 months

Hematopoietic

- Absolute neutrophil count > 1,500/mm^3

- Hemoglobin > 10 g/dL

- Platelet count > 100,000/mm^3

Hepatic

- Bilirubin < 1.5 mg/dL

- SGPT = 2 times upper limit of normal

- No significant hepatic dysfunction

Renal

- Creatinine based on age as follows:

- = 0.8 mg/dL (for patients age 5 years and under)

- = 1.0 mg/dL (for patients age 6 to 10 years)

- = 1.2 mg/dL (for patients age 11 to 15 years)

- = 1.5 mg/dL (for patients age 16 to 21 years) OR

- Creatinine clearance = 70 mL/min

Cardiovascular

- No significant cardiac dysfunction

- No severe cardiovascular disease

- No cardiac arrhythmia requiring chronic treatment

- No congestive heart failure

- No symptomatic ischemic heart disease

Pulmonary

- No significant pulmonary dysfunction

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No serious infection

- No other significant unrelated systemic illness

- No significant organ dysfunction

- No other malignancy except surgically cured nonmelanoma skin cancer or carcinoma in situ of the cervix

- No history of severe psychiatric condition or psychiatric disorder requiring hospitalization

- No history of suicidal ideation or attempt

- No thyroid dysfunction unresponsive to therapy

- No uncontrolled diabetes mellitus

- No history of HIV positivity

- No alcohol or drug abuse

PRIOR CONCURRENT THERAPY:

Biologic therapy

- No concurrent immunotherapy

- No concurrent colony-stimulating factors (e.g., erythropoietin or filgrastim [G-CSF])

Chemotherapy

- No concurrent chemotherapy for this disease

Endocrine therapy

- No concurrent chronic systemic corticosteroids

- No concurrent hormonal therapy for this disease

Radiotherapy

- No concurrent radiotherapy for this disease

Surgery

- Prior surgery allowed provided it has been at least 21 days since surgery and there is presence of residual tumor

Other

- Recovered from prior therapy

- More than 30 days since prior investigational agents

Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
PEG-interferon alfa-2a


Locations

Country Name City State
United States Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda Maryland
United States Children's Memorial Hospital - Chicago Chicago Illinois
United States Children's Hospital of Pittsburgh Pittsburgh Pennsylvania
United States Children's National Medical Center Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
National Institutes of Health Clinical Center (CC) National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Jakacki RI, Dombi E, Potter DM, Goldman S, Allen JC, Pollack IF, Widemann BC. Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas. Neurology. 2011 Jan 18;76(3):265-72. doi: 10.1212/WNL.0b013e318207b031. — View Citation

See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT01164163 - INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Phase 1
Completed NCT00985868 - AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors Phase 1
Terminated NCT00949117 - Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer Phase 2
Completed NCT00281944 - Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors Phase 1
Recruiting NCT00084695 - Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Phase 2
Completed NCT00053963 - FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Phase 1
Completed NCT00003070 - Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer Phase 3
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00003754 - Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers Phase 2
Completed NCT00004005 - Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin Phase 2
Completed NCT00016861 - Irinotecan in Treating Children With Refractory or Progressive Solid Tumors Phase 1
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Recruiting NCT00898794 - Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer N/A
Terminated NCT00429702 - Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy Phase 2
Completed NCT00387920 - Sunitinib in Treating Young Patients With Refractory Solid Tumors Phase 1
Completed NCT00459238 - Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants N/A
Completed NCT00138216 - Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Phase 1
Terminated NCT00176540 - Dextromethorphan in Treating Patients With Fatigue Caused by Cancer N/A
Completed NCT00070473 - Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors Phase 1